- Home
- IMMX vs FBIO Comparison
IMMX vs FBIO Comparison
Compare IMMX & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- FBIO
- Stock Information
- Founded
- IMMX 2014
- FBIO 2006
- Country
- IMMX United States
- FBIO United States
- Employees
- IMMX N/A
- FBIO N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- FBIO Health Care
- Exchange
- IMMX Nasdaq
- FBIO Nasdaq
- Market Cap
- IMMX 82.6M
- FBIO 88.7M
- IPO Year
- IMMX 2021
- FBIO N/A
- Fundamental
- Price
- IMMX $3.28
- FBIO $2.70
- Analyst Decision
- IMMX Strong Buy
- FBIO Strong Buy
- Analyst Count
- IMMX 1
- FBIO 2
- Target Price
- IMMX $8.00
- FBIO $16.50
- AVG Volume (30 Days)
- IMMX 769.8K
- FBIO 393.8K
- Earning Date
- IMMX 11-07-2025
- FBIO 11-12-2025
- Dividend Yield
- IMMX N/A
- FBIO N/A
- EPS Growth
- IMMX N/A
- FBIO N/A
- EPS
- IMMX N/A
- FBIO N/A
- Revenue
- IMMX N/A
- FBIO $59,301,000.00
- Revenue This Year
- IMMX N/A
- FBIO $31.85
- Revenue Next Year
- IMMX N/A
- FBIO $44.43
- P/E Ratio
- IMMX N/A
- FBIO N/A
- Revenue Growth
- IMMX N/A
- FBIO N/A
- 52 Week Low
- IMMX $1.34
- FBIO $1.33
- 52 Week High
- IMMX $4.05
- FBIO $4.20
- Technical
- Relative Strength Index (RSI)
- IMMX 55.27
- FBIO 50.08
- Support Level
- IMMX $2.85
- FBIO $2.39
- Resistance Level
- IMMX $3.53
- FBIO $2.65
- Average True Range (ATR)
- IMMX 0.38
- FBIO 0.12
- MACD
- IMMX -0.07
- FBIO 0.03
- Stochastic Oscillator
- IMMX 34.80
- FBIO 94.03
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.